Etrasimod for Eosinophilic Esophagitis (VOYAGE Trial)

"Presently, there are 7 active clinical trials assessing the efficacy of Etrasimod with 3 in Phase 3. These medical studies span 1131 locations worldwide, though a majority are located in Yvoir and Gyeonggi-do."

"Alas, this clinical trial is no longer seeking new candidates. Initially posted 2/23/2021 and last edited on 7/4/2022, it has now ended its recruitment period. Nevertheless, there are currently 52 trials for eosinophilic esophagitis with open enrolment slots as well as seven research studies involving etrasimod that are still recruiting volunteers."

"Presently, 7 clinical trials involving Etrasimod are operating in 50 countries and 369 cities. Arena Pharmaceuticals initiated the first of these studies back in 2019; it entailed 912 participants, culminating with Phase 3 drug approval. Since then, 18332 experiments have been concluded."

"Patients that meet the criteria for this trial must be between 18 and 65 years old. Separately, 27 clinical trials welcome participants under 18 while 43 accommodate those over 65."

"This clinical trial has since closed recruitment, with its first posting occurring on February 23rd 2021 and the last update being made July 4th 2022. For those seeking other medical trials, there are currently 52 that accept Eosinophilic Esophagitis patients and 7 for Etrasimod enrolment."

"At present, 54 distinct medical centres are running this trial. Locations include Cincinnati, Oklahoma City and Clearwater alongside other sites throughout the country; opting for a site located nearby can reduce travelling requirements for patients that choose to participate."

"There is early clinical evidence that supports etrasimod's safety, so it was assigned a rating of 2."

"This clinical trial is recruiting 108 patients suffering from eosinophilic esophagitis aged between 18 and 65. It's paramount that they meet the following conditions: having completed Week 24 study visit, with an EoE diagnosis earlier than screening, dysphagia episodes of more than two per week on a fortnightly basis during Screening period, no safety issues identified by Investigator in Double-Blind Treatment Period and agreement to comply with Extension Treatment Period’s visits and procedures."